AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio

AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal ... Read More